Surge-on Medical, the Dutch start-up in the minimally invasive surgery sector, will launch its equity crowdfunding campaign on August 27, 2019. The campaign is a joint effort with EIT Health, and the German crowdfunding platform aescuvest.eu.
So far, Surge-on Medical has built a portfolio of minimally invasive instruments based on their patented cable-free steerable mechanism. Through its four patents, Surge-on Medical is active in the arthroscopy, laparoscopy and robotic surgery markets.
Benno Groosman, CEO Surge-on Medical, said: “At Surge-on Medical, we believe that surgeons can do more than current instruments allow. With this in mind, we have developed the next generation of minimally invasive surgical instruments. Through our cable-free platform technology, we created freedimensional instruments that provide better access to surgical areas and replace current pre-bent instrumentation.”
The first product, the Steerable Punch, is an arthroscopic cutter for knee surgery. It’s also developing an advanced laparoscopy line and a portable surgical robot (PoLaRS). All the instruments are based on its patented steerable and cable-free technology, with the potential to grow to more surgical areas to expand the market reach.
EIT Health says the most promising start-ups in the healthcare sector will now have a platform from which to expand their business across Europe. Surge-on Medical is the start-up that will initiate this investment platform.
By joining forces with EIT Health, Surge-on Medical will access decision makers and investors across Europe, thanks to the network of the organisation. Aescuvest provides the experience in digital investment platforms to allow investors to safely participate in handpicked projects audited by an independent investment committee. Through aescuvest.eu, Surge-on Medical expects to raise up to €5 million.
Through this successful campaign, Surge-on Medical expects to launch its large-scale manufacturing of the arthroscopic line of instruments, to launch the Steerable Punch in the European market, to continue the R&D activities of the laparoscopic and robotic lines, and to expand the team into sales and marketing departments.